Clinical Trial Update: Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating intravenous immunoglobulin for amnestic mild cognitive impairment has completed with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment

Drugs mentioned

• Intravenous Immunoglobulin (IVIG)

Snippet

Sponsor: Sutter Health | Conditions: Mild Cognitive Impairment | Phase 2 | Status: COMPLETED | Results posted: 2016-03-31